Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RCKT
ROCKET PHARMACEUTICALS, INC.
NASDAQ
$3.86
▲ UP 1.85% (0.07)

KEY STATISTICS

Market Cap$422.58 M
52w High$5.45
52w Low$2.53
Dividend Yield—
Frequency—
P/E-22.71
Volume888.02K
Shares Out.109.19M

COMPANY

LEADERSHIP

Gaurav D. Shah
CHIEF EXECUTIVE
Gaurav D. Shah

COMPENSATION 2026

Salary$671,076
Stock Awards$806,751
Incentive Plan Pay$403,048
All Other Comp.$15,988
Total$3,510,241

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 18, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
202

PRICE TARGET

Target High$69.00
Target Low$2.00
Target Median$19.50
Target Consensus$23.81

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$200.00K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2018-01-05Reverse1:4

PRICE

$3.86 ▲ UP 1.85% (+$0.07)
OVERLAYS
$3.75$3.80$3.859:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.86

About Rocket Pharmaceuticals, Inc.

https://rocketpharma.com ↗

Rocket Pharmaceuticals develops gene therapies for rare diseases like Fanconi anemia, leukocyte adhesion deficiency, pyruvate kinase deficiency, and Danon disease through multiple clinical-stage programs and strategic collaborations.

INDUSTRY

Biotechnology

A PRODUCT ROCKET PHARMACEUTICALS, INC. IS KNOWN FOR

Kresladi™ (marnetegragene autotemcel)
Kresladi™ (marnetegragene autotemcel)

Kresladi™ is an investigational gene therapy for severe LAD-I, with FDA review underway and a decision expected by March 28, 2026, remaining Rocket Pharmaceuticals' most advanced product despite a strategic shift to cardiovascular pipelines.

COMPETITORS

COMPETITOR
BMRN COMPARE
CRSP COMPARE
RARE COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
92
LISTED HERE
17
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.7M
XSU.TO
0.01% · 2.3M
FESM
0.06% · 933.5K
SCHA
0.01% · 422.5K
PRFZ
0.05% · 330.2K
DFMC
0.01% · 259.3K
R2US.L
0.01% · 204.6K
AVSC
0.01% · 114.2K
BBC
0.86% · 114.1K
FSCC
0.08% · 77.0K
GNOM
0.30% · 73.4K
XRS2.DE
0.01% · 72.9K
WDNA.L
0.29% · 32.2K
RFLR
0.09% · 23.3K
BIB
0.01% · 3.9K
VETS
0.03% · 2.2K
RESM
0.01% · 204

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
283
TOP 12 OF 283 · RANKED BY POSITION SIZE
Healthcor Management, L.P.
68.1M sh · $978.5K
Monarch Partners Asset Management LLC
68.1M sh · $2.23M
Rtw Investments, LP
17.7M sh · $57.66M
Blackrock, Inc.
9.9M sh · $33.94M
Vanguard Group Inc
8.5M sh · $29.99M
Maverick Capital Ltd
8.5M sh · $27.61M
Blackrock Inc.
6.2M sh · $133.33M
Citigroup Inc
5.2M sh · $18.41M
State Street Corp
4.5M sh · $16.06M
Marshall Wace, Llp
4.0M sh · $13.78M
Millennium Management LLC
4.0M sh · $13.68M
Newtyn Management, LLC
4.0M sh · $13.68M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
OFFICER: GENERAL COUNSEL
Wilson Martin
Sale · 631 shares
2026-08-18
★
OFFICER: CEO
Shah Gaurav
Sale · 2.3K shares
2026-08-18
★
OFFICER: GENERAL COUNSEL
Wilson Martin
Sale · 3.5K shares
2026-08-13
★
OFFICER: CEO
Shah Gaurav
Sale · 2.8K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
SELL 1
OVERWEIGHT 1
UNDERWEIGHT 1
MARKET PERFORM 1
7 GRADES IN THE LAST 12 MONTHS
Chardan Capital BUY Wedbush OUTPERFORM B of A Securities BUY Goldman Sachs SELL Cantor Fitzgerald OVERWEIGHT JP Morgan UNDERWEIGHT Leerink Partners MARKET PERFORM

SECTORS PEERS

PEERPRICE
LBRX$49.65COMPARE
SLDB$10.39COMPARE
DSGN$15.29COMPARE
ANNX$4.87COMPARE
AURA$7.54COMPARE
AUTL$2.25COMPARE
DBVT$13.54COMPARE
GALT$4.64COMPARE